Capital Market Strategies LLC Has $1.12 Million Stock Position in Johnson & Johnson (NYSE:JNJ)

Capital Market Strategies LLC boosted its holdings in Johnson & Johnson (NYSE:JNJ) by 5.8% during the 4th quarter, HoldingsChannel.com reports. The institutional investor owned 7,723 shares of the company’s stock after acquiring an additional 425 shares during the quarter. Capital Market Strategies LLC’s holdings in Johnson & Johnson were worth $1,117,000 at the end of the most recent reporting period.

Several other institutional investors have also recently bought and sold shares of the business. Pensionfund Sabic increased its position in Johnson & Johnson by 49.2% during the 4th quarter. Pensionfund Sabic now owns 27,300 shares of the company’s stock worth $3,948,000 after purchasing an additional 9,000 shares in the last quarter. Nordea Investment Management AB grew its stake in shares of Johnson & Johnson by 13.7% during the fourth quarter. Nordea Investment Management AB now owns 6,424,675 shares of the company’s stock worth $926,438,000 after buying an additional 775,490 shares during the last quarter. Versant Capital Management Inc increased its holdings in shares of Johnson & Johnson by 27.8% during the fourth quarter. Versant Capital Management Inc now owns 4,678 shares of the company’s stock worth $677,000 after buying an additional 1,019 shares in the last quarter. Trust Co of the South boosted its holdings in shares of Johnson & Johnson by 5.1% during the 4th quarter. Trust Co of the South now owns 9,672 shares of the company’s stock valued at $1,399,000 after acquiring an additional 470 shares in the last quarter. Finally, SK Wealth Management LLC bought a new stake in Johnson & Johnson during the 3rd quarter worth $234,000. Institutional investors and hedge funds own 69.55% of the company’s stock.

Johnson & Johnson Stock Down 0.2 %

Shares of NYSE:JNJ traded down $0.23 during midday trading on Monday, hitting $143.96. 3,218,931 shares of the company’s stock were exchanged, compared to its average volume of 4,950,570. Johnson & Johnson has a 12 month low of $142.75 and a 12 month high of $168.85. The company has a market cap of $346.60 billion, a PE ratio of 20.83, a price-to-earnings-growth ratio of 2.52 and a beta of 0.51. The company has a debt-to-equity ratio of 0.45, a current ratio of 1.03 and a quick ratio of 0.79. The stock has a 50 day moving average price of $151.40 and a 200-day moving average price of $156.28.

Johnson & Johnson (NYSE:JNJ) last issued its quarterly earnings data on Tuesday, October 15th. The company reported $2.42 EPS for the quarter, topping the consensus estimate of $2.21 by $0.21. The firm had revenue of $22.47 billion during the quarter, compared to the consensus estimate of $22.17 billion. Johnson & Johnson had a return on equity of 35.45% and a net margin of 19.14%. The company’s quarterly revenue was up 5.2% compared to the same quarter last year. During the same period in the prior year, the business posted $2.66 earnings per share. On average, sell-side analysts anticipate that Johnson & Johnson will post 9.94 EPS for the current fiscal year.

Johnson & Johnson Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Tuesday, March 4th. Investors of record on Tuesday, February 18th will be given a dividend of $1.24 per share. This represents a $4.96 dividend on an annualized basis and a dividend yield of 3.45%. The ex-dividend date of this dividend is Tuesday, February 18th. Johnson & Johnson’s payout ratio is currently 71.78%.

Analyst Upgrades and Downgrades

A number of brokerages have recently commented on JNJ. Royal Bank of Canada lifted their price target on Johnson & Johnson from $178.00 to $181.00 and gave the company an “outperform” rating in a research note on Wednesday, October 16th. Cantor Fitzgerald reissued an “overweight” rating and set a $215.00 target price on shares of Johnson & Johnson in a report on Wednesday, October 16th. Citigroup dropped their price target on shares of Johnson & Johnson from $185.00 to $175.00 and set a “buy” rating for the company in a research note on Wednesday, December 11th. Wolfe Research started coverage on shares of Johnson & Johnson in a research note on Friday, November 15th. They issued an “outperform” rating and a $190.00 price objective on the stock. Finally, Bank of America reaffirmed a “neutral” rating and set a $166.00 target price on shares of Johnson & Johnson in a report on Tuesday, December 10th. Seven equities research analysts have rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $174.71.

Insider Buying and Selling

In other Johnson & Johnson news, Director Mark A. Weinberger bought 1,000 shares of the firm’s stock in a transaction dated Thursday, December 12th. The stock was purchased at an average cost of $147.22 per share, with a total value of $147,220.00. Following the transaction, the director now directly owns 1,000 shares in the company, valued at $147,220. This trade represents a ∞ increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. 0.16% of the stock is owned by corporate insiders.

About Johnson & Johnson

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.